Donor Lymphocyte Infusion Post Transplant
Phase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic Malignancies
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 430 patients (estimated)
- Sponsors
- National Cancer Institute (NCI)
- Tags
- Donor Lymphocyte Infusion (DLI), Post-Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 2065
- NCT Identifier
- NCT05327023
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.